CJC-1295 with DAC

CJC-1295 with DAC Peptide Detailed Overview

CJC-1295 with DAC is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C152H252N44O42
Molecular Weight	3367.9 g/mol
Assay Purity	>98.0%
Appearance	Off-white crystalline solid

Figure 1: Conceptual Binding Mechanism of CJC-1295 with DAC

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. Drug Affinity Complex (DAC) covalently bonds to serum albumin post-injection.
2. This albumin bond extends its half-life to approximately 6-8 days.
3. Binds continuously to the GHRH receptor located in the anterior pituitary.
4. Provokes a persistent, elevated baseline level of endogenous Growth Hormone.
5. Causes a corresponding steady increase in systemic IGF-1 output.

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: Creates a slow 'bleed' of growth hormone rather than a pulsatile spike.
• Trial Output: Studied for long-term lipolysis and general endocrine support.
• Diagnostic Core: Considerably increases overall GH area-under-the-curve (AUC) across one week.

Drug Affinity Complex: Extended GHRH Signaling

CJC-1295 with DAC (Drug Affinity Complex) is a 30-amino acid synthetic GHRH analogue conjugated to a maleimidopropionic acid (MPA) reactive group that forms a covalent bond with serum albumin after subcutaneous injection. This DAC technology transforms a peptide with a 30-minute half-life into one with an 8-day effective half-life, producing sustained elevation of GH and IGF-1 levels. The base peptide is a modified GHRH(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 that confer DPP-4 resistance.

1. After SC injection, the MPA-DAC moiety reacts with Lys34 on serum albumin via a Michael addition reaction, forming a stable thioether bond.
2. The albumin-conjugated CJC-1295 circulates with albumin’s 19-day half-life, providing continuous GHRH receptor stimulation over 8–10 days per injection.
3. Sustained GHRH receptor activation on pituitary somatotrophs produces elevated baseline GH levels and amplified endogenous GH pulses.
4. IGF-1 levels rise progressively, reaching steady-state elevation of 1.5–3x baseline after 2–3 weekly injections.
5. Amino acid substitutions at positions 2 (D-Ala) and 8 (Gln) prevent DPP-4 cleavage, while Ala15 and Leu27 improve receptor binding stability.

Pharmacokinetic Profile & Research

• Phase 1 Data: Single-dose studies showed GH area-under-curve (AUC) increased 2–10 fold for 6+ days following a single 30–60 μg/kg SC injection.
• IGF-1 Elevation: Dose-dependent IGF-1 increases of 1.5–3x baseline were sustained for 14+ days, confirming the prolonged pharmacodynamic effect.
• Continuous vs. Pulsatile: The sustained GH elevation from DAC differs from physiological pulsatile secretion. Some research suggests continuous GH elevation favors fat loss, while pulsatile favors lean mass accretion.
• Dosing: Research protocols typically use 2 mg SC once or twice weekly. The long half-life makes precise dosing timing less critical than with non-DAC peptides.
• Storage: Reconstitute with BAC water. Refrigerate at 2–8°C. The DAC moiety is stable in solution for 28+ days under refrigeration.